Specialty Pharmacy

Researchers compared lung cancer care and outcomes, including patient characteristics, stage of cancer at diagnosis, treatment, and overall survival of patients in the United States and England.

Top news of the day from across the health care landscape.

Brain damage can begin early in infection, particularly during untreated infection, and can cause cognitive impairment.

The FDA is taking new steps to ensure products being marketed to protect consumers from the sun’s harmful effects deliver on their promises, starting with warning letters sent to companies marketing products with unproven claims.

Ixekizumab (Taltz, Eli Lilly) is the first and only treatment approved by the FDA for moderate-to-severe plaque psoriasis that includes data on psoriasis involving the genital area in its label.

Data from two phase 3 studies found that emicizumab-kxwh (Hemlibra) prophylaxis controlled bleeds in patients with hemophilia A.

Patients with severe asthma who were treated with dupilumab experienced a reduction in severe exacerbation risk, improved lung function, and reduced dependence on oral corticosteroids.

Top news of the day from across the health care landscape.

Rucaparib, an (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation.

Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses the concerns regarding DIR fees and the impact it may have.

The FDA has announced its approval of avatrombopag (Doptelet, AkaRx) tablets to treat low blood platelet count in adults with chronic liver disease (CLD) who are scheduled to undergo a medical or dental procedure.

Patients with glucocorticoid-induced osteoporosis on glucocorticoid therapy who received denosumab (Prolia) had greater gains in bone mineral density in a phase 3 trial.

Officials with the FDA alerted health care professionals about reduced efficacy for some patients taking pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for metastatic urothelial cancer in ongoing clinical trials.

Top news of the day from across the health care landscape.

Antibiotic-resistant Acinetobacter baumannii infections put children with compromised immune systems in health care settings at greater risk of infections of the lung, urinary tract, and other sites.

Pharmacies are increasingly using collected health data to target advertising to customers or identify needs and purchase patterns.

Mepolizumab (Nucala) consistently improves exacerbation reduction and asthma control in patients with severe eosinophilic asthma.

Opioid-related pharmaceutical payments were associated with an increase in the number of opioids prescribed.

Top news of the day from across the health care landscape.

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses the growth of pharmacy accreditation offerings.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Erenumab-aooe (Aimovig, Amgen) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the molecule that is involved in migraine attacks.

A look at last week's top stories in the world of pharmacy.

Deprivation in patients with chronic obstructive pulmonary disease (COPD) is associated with increased emergency healthcare use, healthcare costs, and mortality rates, according to research.

Dupilumab (Dupixent) significantly improved disease severity in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Community Oncology Alliance survey indicates concern that Medicare Part B reforms will have a negative effect on patient care and drive up costs.

Data from two phase 3 studies showed that esketamine nasal spray demonstrated improvements in depressive symptoms for patients who did not respond to other antidepressant treatments.

Top news of the day from across the health care landscape.

COPD prevalence is increasing more rapidly in women, particularly in younger women, and COPD-related hospitalizations and deaths in women also surpass men.